A Phase II Study Investigating Treatment of Post-Allogeneic Transplant Progression or Relapse of CLL or NHL With Lenalidomide Alone or With Rituximab.
Phase of Trial: Phase II
Latest Information Update: 31 Jul 2017
At a glance
- Drugs Rituximab (Primary) ; Lenalidomide
- Indications Chronic lymphocytic leukaemia; Lymphoid leukaemia; Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 01 Sep 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 18 May 2012 Actual initiation date (May 2012) added as reported by ClinicalTrials.gov.
- 18 May 2012 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.